{"organizations": [], "uuid": "ea63f83f93c3ee6b64dc651527351cbb8dde29c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-licenses-i/brief-juniper-pharmaceuticals-licenses-intravaginal-ring-platform-to-dar-bioscience-idUSFWN1S212W", "country": "US", "domain_rank": 408, "title": "BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-04-25T20:10:00.000+03:00", "replies_count": 0, "uuid": "ea63f83f93c3ee6b64dc651527351cbb8dde29c3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-licenses-i/brief-juniper-pharmaceuticals-licenses-intravaginal-ring-platform-to-dar-bioscience-idUSFWN1S212W", "ord_in_thread": 0, "title": "BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ivr", "sentiment": "negative"}, {"name": "juniper pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Juniper Pharmaceuticals Inc:\n* JUNIPER PHARMACEUTICALS LICENSES INTRAVAGINAL RING (IVR) PLATFORM TO DARÉ BIOSCIENCE\n* JUNIPER PHARMACEUTICALS - ELIGIBLE TO RECEIVE UP TO $43.75 MILLION IN MILESTONES FOR EACH IVR CANDIDATE, PLUS ROYALTIES ON FUTURE SALES\n* JUNIPER PHARMACEUTICALS - UNDER AGREEMENT, DARÉ TO BE RESPONSIBLE FOR CONDUCTING ALL RESEARCH, DEVELOPMENT, AND COMMERCIAL ACTIVITIES FOR PROGRAM Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T20:10:00.000+03:00", "crawled": "2018-04-26T21:01:53.064+03:00", "highlightTitle": ""}